Allopregnanolone Protects Against Dopamine-Induced Striatal Damage After In Vitro Ischaemia via Interaction at GABA A Receptors

Journal of Neuroendocrinology

Volumn 24, Issue 8, 2012, Pages 1135-1143

  Knight, S R ^a   Davidson, C ^b   Young, A M J ^a   Gibson, C L ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Dopamine; Neuroactive steroids; Progestogens; Steroids

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID A RECEPTOR; BICUCULLINE; DOPAMINE; MUSCIMOL;

ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; CYCLIC POTENTIOMETRY; DOPAMINE RELEASE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG RECEPTOR BINDING; HORMONE RECEPTOR INTERACTION; IN VITRO STUDY; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BRAIN ISCHEMIA; CORPUS STRIATUM; DOPAMINE; GABA AGONISTS; MALE; MICE; PREGNANOLONE; RECEPTORS, GABA-A;

EID: 84863591451     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2012.02319.x     Document Type: Article

References (49)

1. Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003; 4: 399-415.
2. Dirnagl U. Bench to bedside: the quest for quality in experimental stroke research. J Cereb Blood Flow Metab 2006; 26: 1465-1478.
3. Wardlaw JM, Murray V, Berge E, del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2009; 1: 1-2.
4. Paganini-Hill A. Oestrogen replacement therapy and stroke. Prog Cardiovasc Dis 1995; 38: 223-242.
5. Sacco RL, Benjamin EJ, Broderick JP, Dyken M, Easton JD, Feinberg WM, Goldstein LB, Gorelick PB, Howard G, Kittner SJ, Manolio TA, Whisnant JP, Wolf PA. American Heart Association Prevention Conference. IV. Prevention and rehabilitation of stroke. Risk factors. Stroke 1997; 28: 1507-1517.
6. Thorvaldsen P, Asplund K, Kuulasmaa K, Rajakangas AM, Schroll M. Stroke incidence, case fatality, and mortality in the WHO MONICA project. World Health Organization monitoring trends and determinants in cardiovascular disease. Stroke 1995; 26: 361-367.
7. Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med 1993; 329: 247-256.
8. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen T, Curb JD, Black H, Rossouw JE, Aragaki A, Safford M, Stein E, Laowattana S, Mysiw WJ, Whi I. Effect of oestrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003; 289: 2673-2684.
9. Bath PM, Gray LJ. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ 2005; 330: 342.
10. Wright DW, Kellermann AL, Hertzberg VS, Clark PL, Frankel M, Goldstein FC, Salomone JP, Dent LL, Harris OA, Ander DS, Lowery DW, Patel MM, Denson DD, Gordon AB, Wald MM, Gupta S, Hoffman SW, Stein DG. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med 2007; 49: 391-402.
11. Xiao G, Wei J, Yan W, Wang W, Lu Z. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit Care 2008; 12: R61.
12. Gibson CL, Murphy SP. Progesterone enhances functional recovery following middle cerebral artery occlusion. J Cereb Blood Flow Metab 2004; 24: 805-813.
13. Gibson CL, Gray LJ, Bath PM, Murphy SP. Progesterone for the treatment of experimental brain injury; a systematic review. Brain 2008; 131: 318-328.
14. Schumacher M, Guennoun R, Stein DG, De Nicola AF. Progesterone: therapeutic opportunities for neuroprotection and myelin repair. Pharmacol Ther 2007; 116: 77-106.
15. Sayeed I, Stein DG. Progesterone as a neuroprotective factor in traumatic and ischemic brain injury. Prog Brain Res 2009; 175: 219-237.
16. Gibson CL, Coomber B, Rathbone J. Is progesterone a candidate neuroprotective factor for treatment following ischaemic stroke? Neuroscientist 2009; 15: 324-332.
17. A receptor. Nat Rev Neurosci 2005; 6: 565-575.
18. Lockhart EM, Warner DS, Pearlstein RD, Penning DH, Mehrabani S, Boustany RM. Allopregnanolone attenuates N-methyl-d-aspartate-induced excitotoxicity and apoptosis in the human NT2 cell line in culture. Neurosci Lett 2002; 328: 33-36.
19. Sayeed I, Guo Q, Hoffman SW, Stein DG. Allopregnanolone, a progesterone metabolite, is more effective than progesterone in reducing cortical infarct volume after transient middle cerebral artery occlusion. Ann Emerg Med 2006; 47: 381-389.
20. Benveniste H. The excitotoxin hypothesis in relation to cerebral ischaemia. Cerebrovasc Brain Metab Rev 1991; 3: 213-245.
21. Globus MY, Busto R, Martinez E, Valdes I, Dietrich WD, Ginsberg MD. Comparative effect of transient global ischaemia on extracellular levels of glutamate, glycine, and gamma-aminobutyric acid in vulnerable and nonvulnerable brain regions in the rat. J Neurochem 1991; 57: 470-478.
22. Lieb K, Andrae J, Reisert I, Pilgrim C. Neurotoxicity of dopamine and protective effects of the NMDA receptor antagonist AP-5 differ between male and female dopaminergic neurons. Exp Neurol 1995; 134: 222-229.
23. Toner CC, Stamford JA. 'Real time' measurement of dopamine release in an in vitro model of neostriatal ischaemia. J Neurosci Methods 1996; 67: 133-140.
24. Globus MY, Ginsberg MD, Dietrich WD, Busto R, Scheinberg P. Substantia nigra lesion protects against ischaemic damage in the striatum. Neurosci Lett 1987; 80: 251-256.
25. Buisson A, Callebert J, Mathieu E, Plotkine M, Boulu RG. Striatal protection induced by lesioning the substantia nigra of rats subjected to focal ischaemia. J Neurochem 1992; 59: 1153-1157.
26. Toner CC, Stamford JA. Effects of anaesthetic drugs on dopamine release in a model of hypoxia and hypoglycaemia. Br J Anaesth 1995; 75: 660.
27. Mathews KS, Toner CC, McLaughlin DP, Stamford JA. Comparison of ketamine stereoisomers on tissue metabolic activity in an in vitro model of global cerebral ischaemia. Neurochem Int 2001; 38: 367-372.
28. Toner CC, Connelly K, Whelpton R, Bains S, Michael-Titus AT, McLaughlin DP, Stamford JA. Effects of sevoflurane on dopamine, glutamate and aspartate release in an in vitro model of cerebral ischaemia. Br J Anaesth 2001; 86: 550-554.
29. Toner CC, Milne AJ, Blatchford KL, McLaughlin DP, Stamford JA. An assessment of the cerebroprotective potential of volatile anaesthetics using two independent methods in an in vitro model of cerebral ischaemia. Brain Res 2002; 958: 390-398.
30. Davidson C, Coomber B, Gibson CL, Young AMJ. Effect of pre-ischaemic conditioning on hypoxic depolarization of DA efflux in the rat caudate brain slice measured in real-time with fast cyclic voltammetry. Neurochem Int 2011; 59: 214-221.
31. Davidson C, Chauhan N, Knight S, Gibson CL, Young AMJ. Modelling ischaemia in vitro: effects of temperature and glucose concentration on dopamine release evoked by oxygen and glucose deprivation in a mouse brain slice. J Neurosci Methods 2011; 202: 165-172.
32. Stamford JA. Fast cyclic voltammetry: measuring transmitter release in 'real time'. J Neurosci Methods 1990; 34: 67-72.
33. Bickler PE, Warner DS, Stratmann G, Schuyler JA. Gamma-aminobutyric acid-A receptors contribute to isoflurane neuroprotection in organotypic hippocampal cultures. Anesth Analg 2003; 97: 564-571.
34. Mathews KS, McLaughlin DO, Ziabari LH, Toner CC, Street PC, Hisgrove E, Bezzina EL, Stamford JA. Rapid quantification of ischaemic injury and cerebroprotection in brain slices using densitometric assessment of 2, 3, 5-triphenyltetrazolium chloride staining. J Neurosci Methods 2000; 102: 43-51.
35. Benedek A, Moricz K, Juranyi Z, Gigler G, Levay G, Harsing LG, Matyus P, Szenasi G, Albert M. Use of TTC staining for the evaluation of tissue injury in the early phases of reperfusion after focal cerebral ischaemia in rats. Brain Res 2006; 1116: 159-165.
36. Ginsberg MD, Sternau LL, Globus MY, Dietrich WD, Busto R. Therapeutic modulation of brain temperature: relevance to ischaemic brain injury. Cerebrovasc Brain Metab Rev 1992; 4: 189-225.
37. Hosie AM, Wilkins ME, da Silva HM, Smart TG. Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites. Nature 2006; 444: 486-489.
38. Zheng P. Neuroactive steroid regulation of neurotransmitter release in the CNS: action, mechanism and possible significance. Prog Neurobiol 2009; 89: 134-152.
39. Wohlfarth KM, Bianchi MT, Macdonald RL. Enhanced neurosteroid potentiation of ternary GABA(A) receptors containing the delta subunit. J Neurosci 2002; 22: 1541-1549.
40. Cross AJ, Jones JA, Snares M, Jostell KG, Bredberg U, Green AR. The protective action of chlormethiazole against ischaemia-induced neurodegeneration in gerbils when infused at doses having little sedative or anticonvulsant activity. Br J Pharmacol 1995; 114: 1625-1630.
41. Lyden PD. GABA and neuroprotection. Int Rev Neurobiol 1997; 40: 233-258.
42. Marshall JW, Cross AJ, Ridley RM. Functional benefit from clomethiazole treatment after focal cerebral ischaemia in a nonhuman primate species. Exp Neurol 1999; 156: 121-129.
43. A receptor. Anesthesiology 1999; 91: 500-511.
44. Djebaili M, Hoffman SW, Stein DG. Allopregnanolone and progesterone decrease cell death and cognitive deficits after a contusion of the rat pre-frontal cortex. Neuroscience 2004; 123: 349-359.
45. He J, Evans C-O, Hoffman SW, Oyesiku NM, Stein DG. Progesterone and allopregnanolone reduce inflammatory cytokines after traumatic brain injury. Exp Neurol 2004; 189: 404-412.
46. Gibson CL, Constantin D, Prior MJW, Bath PMW, Murphy SP. Progesterone suppresses the inflammatory response and nitric oxide synthase-2 expression following cerebral ischemia. Exp Neurol 2005; 193: 522-530.
47. Ishrat T, Sayeed I, Atif F, Hua F, Stein DG. Progesterone and allopregnanolone attenuate blood-brain barrier dysfunction following permanent focal ischaemia by regulating the expression of matrix mellatoproteinases. Exp Neurol 2010; 226: 183-190.
48. Danton GH, Dietrich WD. Inflammatory mechanisms after ischaemia and stroke. J Neuropathol Exp Neurol 2003; 62: 127-136.
49. Cole DJ, Drummon JC, Ghazal EA, Shapiro HM. A reversible component of cerebral injury as identified by the histochemical stain 2, 3, 5-triphenyltetrazolium chloride (TTC). Acta Neuropathol 1990; 80: 152-155.